ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

VVOS Vivos Therapeutics Inc

2,63
0,00 (0,00%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Vivos Therapeutics Inc VVOS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% 2,63 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,70 2,56 2,715 2,63 2,63
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/4/202413:30GLOBEVivos Therapeutics’ Flagship CARE Oral Medical Devices..
28/3/202421:05GLOBEVivos Therapeutics Reports Fourth Quarter and Full Year 2023..
28/3/202412:30GLOBEVivos Therapeutics Schedules Release of Fourth Quarter and..
15/2/202414:55EDGAR2Form 8-K - Current report
15/2/202414:00GLOBEVivos Therapeutics Announces Exercise of Warrants for..
14/2/202423:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202413:30GLOBEVivos Therapeutics Highlights Significant Favorable Market..
08/1/202413:30GLOBEVivos Therapeutics Sees Positive Preliminary Metrics..
11/12/202313:30GLOBEVivos Therapeutics Presents Groundbreaking Event:..
04/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
01/12/202322:12EDGAR2Form 424B1 - Prospectus [Rule 424(b)(1)]
30/11/202322:05EDGAR2Form 8-K - Current report
30/11/202322:03EDGAR2Form S-1/A - General form for registration of securities..
29/11/202313:30GLOBEVivos Therapeutics Receives First Ever FDA 510(k) Clearance..
22/11/202322:46EDGAR2Form S-1 - General form for registration of securities under..
14/11/202322:05GLOBEVivos Therapeutics Reports Third Quarter 2023 Financial..
09/11/202322:30GLOBEVivos Therapeutics Schedules Release of Third Quarter 2023..
03/11/202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/11/202322:10EDGAR2Form 8-K - Current report
02/11/202322:00GLOBEVivos Therapeutics Closes $4 Million Private Placement
31/10/202313:00GLOBEVivos Therapeutics Announces Pricing of $4 Million Private..
27/10/202322:15EDGAR2Form 8-K - Current report
26/10/202313:30GLOBEVivos Therapeutics Announces Reverse Stock Split
24/10/202313:30GLOBEVivos Therapeutics Signs Nationwide Distribution Agreement..
11/10/202313:30GLOBEVivos Therapeutics to Begin Clinical Trial at Stanford..
05/10/202313:30GLOBEVivos Therapeutics Announces Strategic Collaboration in the..
04/10/202321:55APSBiotech Soars On New Agreements
04/10/202313:30GLOBEVivos Therapeutics Executes Strategic Agreements with Ormco..
02/10/202313:30GLOBENew York Times Best-Selling Author James Nestor to Headline..
25/9/202315:00EDGAR2Form 8-K - Current report
21/9/202323:10EDGAR2Form 8-K - Current report
14/9/202322:38EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/9/202323:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202315:00EDGAR2Form DEF 14A - Other definitive proxy statements
21/8/202315:00EDGAR2Form 8-K - Current report
16/8/202322:45EDGAR2Form PRE 14A - Other preliminary proxy statements
16/8/202322:30EDGAR2Form 8-K - Current report
16/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/8/202322:05GLOBEVivos Therapeutics Reports Second Quarter 2023 Financial..
16/8/202313:30GLOBEVivos Therapeutics Reschedules Second Quarter 2023 Financial..
14/8/202323:06GLOBEVivos Therapeutics to Reschedule Second Quarter 2023..
11/8/202302:31GLOBEVivos Therapeutics Schedules Release of Second Quarter 2023..
08/6/202322:05GLOBEVivos Therapeutics Reports First Quarter 2023 Financial..
06/6/202322:30GLOBEVivos Therapeutics Schedules Release of First Quarter..
09/5/202313:30GLOBEVivos Therapeutics Announces Additional Strategic..

Dernières Valeurs Consultées

Delayed Upgrade Clock